Companies › Alpha Cognition
1 active drug program in 1 registered trial: 1 Phase 4; Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Benzgalantamine Acetylcholinesterase inhibitor | ACHE | Phase 4 | Alzheimer Disease | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07633470 | Benzgalantamine | Phase 4 | Alzheimer Disease | Neurology | Apr 2027 |
Cash of $41m on 2026-06-30; operating cash outflow about $38m a year; runway about 13 months at that burn, to Aug 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Supernus Pharmaceuticals Wanbangde Pharmaceutical Group Inventage Lab.
Wanbangde Pharmaceutical Group Immunic NervGen Pharma Satellos Bioscience Coya Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.